^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Hercessi (trastuzumab-strf) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    PRNewswire
    Title:

    Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer

    Published date:
    09/18/2024
    Excerpt:
    ...the U.S. Food and Drug Administration (FDA) has approved a 420mg strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.